ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), today commenced dosing of two cohorts in the U.S. as part of ...
News-Medical.Net on MSN
New trial aims to improve both survival and quality of life for men with advanced prostate cancer
The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...
Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...
PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.
New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...
A new way to prevent excruciating pain from the side effects of advanced prostate cancer therapy has been developed.Many men ...
Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...
-- Curium's Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the ...
Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback